Scailyte uses AI and single-cell data to discover biomarkers for therapy response, diagnosis, and disease severity.

Scailyte

Single cell technology - beginning of a new era in the clinical biomarker discovery 

True precision medicine through single-cell science. 

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human's hidden "single-cell"​ secrets. The performance and clinically-relevant application of Scailyte's platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women's health supported by  top clinicians and access to high quality proprietary datasets.
If you want to partner with us and save lives by enabling precision medicine, reach out to contact@scailyte.com
 
More information about our company, technology & services you can find on our website - https://scailyte.com

MassChallenge

Venture Kick

Innosuisse

Verve Ventures

4FO Ventures

Hemex

Swisscom Ventures

Mirabaud

🔊 We never shared the efforts we put in developing our pipeline but this time we want to recognize this achievement: 

💡 ScaiTrack: a tool to trace and reproduce our analyses.

🤓 While developing tools like ScaiTrack could be considered extraneous to our primary goal of discovering biomarkers from single-cell data, we believe that this work is integral to ensuring the quality of what we deliver to our partners. It reflects how we live one of Scailyte’s core company values: Passion for quality that matters. 
With ever-more-complex AI tools and methods constantly being released, reproducibility and traceability have become more important than ever as a cornerstone of credible and reliable data analysis. Not only does reproducibility allow for an independent verification of results and detection of potential errors or biases, it promotes transparency in scientific research, building trust within the community.
At Scailyte, we’ve taken steps in the past to improve reproducibility in our algorithms and machine learning models, such as fixing a seed to ensure deterministic behavior. However, this could be considered “low-hanging fruit”, because as much as we would like to avoid it, irreproducibility often arises due to human actions during the course of a data analysis project - the small things that a data scientist does slightly differently from one analysis to another. We built a tool to help us track our analysis process, which we call ScaiTrack. 
When a data scientist activates ScaiTrack, it records all of the commands that he or she runs on the command line along with all outputs and the time at which commands were issued. Moreover, it can filter out commands like *ls* and *cd* which don’t modify the content or structure of any files on the system, keeping only the “important” commands for easy lookup. On top of that, it allows our data scientists to log the complete list of packages installed, monitor any changes that occur to specified files, and detail the differences made after file editing with a text editor like vim. With this tool, we can easily trace back all of the actions we’ve taken in order to ensure traceability and reproducibility of our results. 
Our robust Quality Management System (compliant with ISO9001 and key regulations of HIPAA, GDPR, GCP, GLP), as well as very comprehensive data protection and cybersecurity policies and infrastructure, underscore our dedication to deliver robust and reproducible results in compliance with industry standards and handle sensitive patient data with utmost care.

📬 Reach out to us if you want to learn more about ScaiVision and how we can partner! contact@scailyte.com

🔍 Unveiling Insights into T cell subsets in ICI-associated adverse events: Exploring the Latest Research in Single-Cell Technologies! 🧬

We're thrilled to share the latest instalment of our ScaiDigest series! In this volume, we delve into two recent articles using single-cell transcriptomic data to analyse the contribution of different imune cell subsets to ICI-induced colitis.
Sukalp is thrilled to provide a summary & his perspective of these two papers for our ScaiDigest.

💡 Don't miss out on these highlights! Dive into Sukalp's commentary on the complex biology of ICIs using multiomic approach!

#ScaiDigest , #SingleCellTechnologies #Innovation #Healthcare 
#singlecell #biomarkers #oncology #immunotherapy

🔍 Unveiling Insights into Immunoprofiling in prediction of immunotherapy response: Exploring the Latest Research in Single-Cell Technologies! 🧬

We're thrilled to share the latest instalment of our ScaiDigest series! In this volume, we delve into BostonGene's description of 5 immunotypes conserved among different cancer indications using proteomic and transcriptomic data from blood to stratify treatment responses of cancer patients.
Diana is thrilled to provide a summary & her perspective of this new paper for our ScaiDigest.

💡 Don't miss out on this captivating read! Dive into Diana's commentary on the significant role of comprehensive immunoprofiling using multiomic approach to predict disease and therapy outcomes.

📖 Read the full post below:

#ScaiDigest , #SingleCellTechnologies #Innovation #Healthcare 
#singlecell #biomarkers #oncology #immunotherapy

Last week I was at the #BIO2024 exploring partnership opportunities with biotech & pharma companies from around the world. This was a very well organized, vibrant & colorful event in the emerging biotech hub San Diego. Some key insights:
- biomarker-driven drug discovery and companion diagnostics is gaining importance outside of oncology, in particular in auto-immunity;
- there is a new wave of immuno-oncology drugs, which are showing very promising results with overall response rates of >80% and complete response in >40% of patients in early clinical trials.
- genAI and large language models are a hype also in the biotech space - a lot of talk with no results or solid science to back up the claims of these new genAI companies - the bubble gets inflated.

🔍 Unveiling Insights into Epigenetic Regulation of Tumorigenesis: Exploring the Latest Research in Single-Cell Technologies! 🧬

We're thrilled to share the latest instalment of our ScaiDigest series! In this volume, we delve into the fascinating world of the regulation of Polycomb, shedding light on the complexity of tumorigenesis. Our CEO Peter Nestorov studied the role of Polycomb regulation during his PhD work and he pioneered the use of single-cell RNAseq to understand the complex and heterogeneous effects of epigenetic regulation. Still fascinated by Polycomb, Peter was thrilled to provide a summary & his perspective of this new paper for our ScaiDigest.

💡 Don't miss out on this captivating read! Dive into Peter's commentary on the significant role of epigenetic changes, particularly those mediated by Polycomb proteins, in driving malignant transformation.

📖 Read the full post below:

#ScaiDigest #SingleCellTechnologies #Research #Innovation #Healthcare #epigenetics #singlecell #biomarkers #oncology

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where business and breakthroughs converge.

🤝 We aim to establish strategic co-development partnerships with clinical-stage biotech and pharma to jointly deliver precision medicine solutions to patients in oncology and auto-immunity.
💊 We are generating a large single-cell omics data lake in immuno-oncology, which will catalyze our strategic partnerships and we are also looking for further out-licensing partnerships around this unique dataset.

At Scailyte, we aim to improve clinical outcomes and shorten the drug development process by leveraging single-cell technologies and our proprietary AI platform ScaiVision. Using our cluster-free, unbiased, and highly sensitive AI platform, we have built unique discovery and translational capabilities and a pipeline of precision biomarkers in immunology, oncology, cell and gene therapies.

📣 Attending BIO 2024? Click below to send Scailyte a meeting request in the BIO partnering system!
https://lnkd.in/dmNn3btx

#BIO2024 #BiomarkerDiscovery #AI #MeetScailyte #JoinTheConversation #ScaiVision #ScaiPod #singlecell #precisionmedicine #biomarkers #CGT

Metric
Company Name	Scailyte
Symbol
MSH ID	COM:SCAILYTE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CH
Stage
Employee Count	23
Website	scailyte.com
LinkedIn	scailyte
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SCAILYTE

Scailyte

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue